
Chinese biopharmaceutical company established on 29 April 2014 with 229.77 million yuan of registered capital and headquartered on Shengrong Road in Pudong New Area, Shanghai, with a research centre in Suzhou BioBay and offices in Beijing and Sydney. Focuses on unmet needs in respiratory and lung disease and paediatric medicine, aiming to become a global platform for antiviral innovative drugs and children's medicines. Its pipeline, built through in-house research and in-licensing, is led by the respiratory syncytial virus programme around ziresovir and an antifibrotic portfolio led by AK3280.
会社プロフィールを見る
評価を残す